1
|
Weissman R, Diamond EL, Haroche J, Pillar N, Shapira G, Durham BH, Buthorn J, Cohen F, Ki M, Stemer G, Ulaner GA, Amoura Z, Emile JF, Mazor RD, Shomron N, Abdel-Wahab OI, Shpilberg O, Hershkovitz-Rokah O. The Contribution of MicroRNAs to the Inflammatory and Neoplastic Characteristics of Erdheim-Chester Disease. Cancers (Basel) 2020; 12:E3240. [PMID: 33153128 PMCID: PMC7693724 DOI: 10.3390/cancers12113240] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Revised: 10/27/2020] [Accepted: 10/30/2020] [Indexed: 01/18/2023] Open
Abstract
The pathogenesis of histiocytic neoplasms is driven by mutations activating the MAPK/ERK pathway, but little is known about the transcriptional and post-transcriptional alterations involved in these neoplasms. We analyzed microRNA (miRNA) expression in plasma samples and tissue biopsies of Erdheim-Chester disease (ECD) and Langerhans cell histiocytosis (LCH) patients. In silico analysis revealed a potential role of miRNAs in regulating gene expression in these neoplasms as compared with healthy controls (HC). NanoString analysis revealed 101 differentially expressed plasma miRNAs in 16 ECD patients as compared with 11 HC, 95% of which were downregulated. MiRNAs-15a-5p, -15b-5p, -21-5p, -107, -221-3p, -320e, -630, and let-7 family miRNAs were further evaluated by qRT-PCR in an extended cohort of 32 ECD patients, seven LCH and 15 HC. Six miRNAs (let-7a, let-7c, miR-15a-5p, miR-15b-5p, miR-107 and miR-630) were highly expressed in LCH plasma and tissue samples as compared with ECD. Pathway enrichment analysis indicated the miRNA contribution to inflammatory and pro-survival signaling pathways. Moreover, the let-7 family members were downregulated in untreated ECD patients as compared with HC, while treatment with MAPK/ERK signaling inhibitors for 16 weeks resulted in their upregulation, which was in parallel with the radiologic response seen by PET-CT. The study highlights the potential contribution of miRNA to the inflammatory and neoplastic characteristics of ECD and LCH.
Collapse
Affiliation(s)
- Ran Weissman
- Department of Molecular Biology, Faculty of Natural Sciences, Ariel University, Ariel 40700, Israel;
- Translational Research Lab, Assuta Medical Centers, Tel-Aviv 6971028, Israel;
| | - Eli L. Diamond
- Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10016, USA; (E.L.D.); (J.B.)
| | - Julien Haroche
- Service de Médecine Interne, Hôpital Universitaire Pitié Salpêtrière-Charles Foix, Sorbonne Université, Faculté de Médecine, 75013 Paris, France; (J.H.); (F.C.); (Z.A.)
| | - Nir Pillar
- Department of Pathology, Hadassah Medical Center and Hebrew University, Jerusalem 91120, Israel;
| | - Guy Shapira
- Edmond J. Safra Center of Bioinformatics, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel; (G.S.); (N.S.)
| | - Benjamin H. Durham
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10016, USA; (B.H.D.); (M.K.); (O.I.A.-W.)
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10016; USA
| | - Justin Buthorn
- Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10016, USA; (E.L.D.); (J.B.)
| | - Fleur Cohen
- Service de Médecine Interne, Hôpital Universitaire Pitié Salpêtrière-Charles Foix, Sorbonne Université, Faculté de Médecine, 75013 Paris, France; (J.H.); (F.C.); (Z.A.)
| | - Michelle Ki
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10016, USA; (B.H.D.); (M.K.); (O.I.A.-W.)
| | - Galia Stemer
- HaEmek Medical Center, Department of Hematology, Afula 1834111, Israel;
| | - Gary A. Ulaner
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10016, USA;
| | - Zahir Amoura
- Service de Médecine Interne, Hôpital Universitaire Pitié Salpêtrière-Charles Foix, Sorbonne Université, Faculté de Médecine, 75013 Paris, France; (J.H.); (F.C.); (Z.A.)
| | - Jean-François Emile
- Research Unit EA4340, Versailles University, Paris-Saclay University, 92104 Boulogne, France;
- Pathology Department, Ambroise Paré Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), 92104 Boulogne, France
| | - Roei D. Mazor
- Assuta Medical Centers, Institute of Hematology/Clinic of Histiocytic Neoplasms, Tel-Aviv 6971028, Israel;
| | - Noam Shomron
- Edmond J. Safra Center of Bioinformatics, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel; (G.S.); (N.S.)
| | - Omar I. Abdel-Wahab
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10016, USA; (B.H.D.); (M.K.); (O.I.A.-W.)
| | - Ofer Shpilberg
- Translational Research Lab, Assuta Medical Centers, Tel-Aviv 6971028, Israel;
- Assuta Medical Centers, Institute of Hematology/Clinic of Histiocytic Neoplasms, Tel-Aviv 6971028, Israel;
- Department of Medicine, Adelson School of Medicine, Ariel University, Ariel 40700, Israel
| | - Oshrat Hershkovitz-Rokah
- Department of Molecular Biology, Faculty of Natural Sciences, Ariel University, Ariel 40700, Israel;
- Translational Research Lab, Assuta Medical Centers, Tel-Aviv 6971028, Israel;
| |
Collapse
|
2
|
Beheshti A, Stevenson K, Vanderburg C, Ravi D, McDonald JT, Christie AL, Shigemori K, Jester H, Weinstock DM, Evens AM. Identification of Circulating Serum Multi-MicroRNA Signatures in Human DLBCL Models. Sci Rep 2019; 9:17161. [PMID: 31748664 PMCID: PMC6868195 DOI: 10.1038/s41598-019-52985-x] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2019] [Accepted: 10/21/2019] [Indexed: 12/12/2022] Open
Abstract
There remains a need to identify new sensitive diagnostic and predictive blood-based platforms in lymphoma. We previously discovered a novel circulating microRNA (miRNA) signature in a Smurf2-deficient mouse model that spontaneously develops diffuse large B-cell lymphoma (DLBCL). Herein, we investigated this 10-miRNA signature (miR-15a, let-7c, let-7b, miR-27a, miR-10b, miR-18a, miR-497, miR-130a, miR24, and miR-155) in human lymphoma cell lines, mice engrafted with patient-derived xenografts (PDXs), and DLBCL patient serum samples leveraging systems biology analyses and droplet digital PCR (ddPCR) technology. Overall, 90% of the miRNAs were enriched in PDX DLBCL models and human lymphoma cell lines. Circulating miRNAs from the serum of 86 DLBCL patients were significantly increased compared with healthy controls and had similar patterns to the murine models. Strikingly, miRNAs were identified up to 27-fold higher levels in the serum of PDX-bearing mice and human patients compared with lymphoma cell lysates, suggesting a concentration of these factors over time within sera. Using cut-points from recursive partitioning analysis, we derived a 5-miRNA signature (let-7b, let-7c, miR-18a, miR-24, and miR-15a) with a classification rate of 91% for serum from patients with DLBCL versus normal controls. In addition, higher levels of circulating let-7b miRNA were associated with more advanced stage disease (i.e., III-IV vs. I-II) in DLBCL patients and higher levels of miR-27a and miR-24 were associated with MYC rearrangement. Taken together, circulating multi-miRNAs were readily detectable in pre-clinical cell line and human lymphoma models as well as in DLBCL patients where they appeared to distinguish clinico-pathologic subtypes and disease features.
Collapse
Affiliation(s)
- Afshin Beheshti
- WYLE, NASA Ames Research Center, Moffett Field, CA, USA. .,Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. .,Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
| | - Kristen Stevenson
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| | - Charles Vanderburg
- Harvard Medical School, Boston, MA, USA.,Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Dashnamoorthy Ravi
- Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
| | - J Tyson McDonald
- Cancer Research Center and Department of Physics, Hampton University, Virginia, USA
| | - Amanda L Christie
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
| | - Kay Shigemori
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
| | - Hallie Jester
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
| | - David M Weinstock
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| | - Andrew M Evens
- Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
| |
Collapse
|
3
|
Beheshti A, Vanderburg C, McDonald JT, Ramkumar C, Kadungure T, Zhang H, Gartenhaus RB, Evens AM. A Circulating microRNA Signature Predicts Age-Based Development of Lymphoma. PLoS One 2017; 12:e0170521. [PMID: 28107482 PMCID: PMC5249061 DOI: 10.1371/journal.pone.0170521] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2016] [Accepted: 01/05/2017] [Indexed: 12/20/2022] Open
Abstract
Extensive epidemiological data have demonstrated an exponential rise in the incidence of non-Hodgkin lymphoma (NHL) that is associated with increasing age. The molecular etiology of this remains largely unknown, which impacts the effectiveness of treatment for patients. We proposed that age-dependent circulating microRNA (miRNA) signatures in the host influence diffuse large B cell lymphoma (DLBCL) development. Our objective was to examine tumor development in an age-based DLBCL system using an inventive systems biology approach. We harnessed a novel murine model of spontaneous DLBCL initiation (Smurf2-deficient) at two age groups: 3 and 15 months old. All Smurf2-deficient mice develop visible DLBCL tumor starting at 15 months of age. Total miRNA was isolated from serum, bone marrow and spleen and were collected for all age groups for Smurf2-deficient mice and age-matched wild-type C57BL/6 mice. Using systems biology techniques, we identified a list of 10 circulating miRNAs being regulated in both the spleen and bone marrow that were present in DLBCL forming mice starting at 3 months of age that were not present in the control mice. Furthermore, this miRNA signature was found to occur circulating in the blood and it strongly impacted JUN and MYC oncogenic signaling. In addition, quantification of the miRNA signature was performed via Droplet Digital PCR technology. It was discovered that a key miRNA signature circulates throughout a host prior to the formation of a tumor starting at 3 months old, which becomes further modulated by age and yielded calculation of a ‘carcinogenic risk score’. This novel age-based circulating miRNA signature may potentially be leveraged as a DLBCL risk profile at a young age to predict future lymphoma development or disease progression as well as for potential innovative miRNA-based targeted therapeutic strategies in lymphoma.
Collapse
Affiliation(s)
- Afshin Beheshti
- Division of Hematology/Oncology, Molecular Oncology Research Institute, Tufts Medical Center, Boston, Massachusetts, United States of America
| | - Charles Vanderburg
- Harvard NeuroDiscovery Center, Massachusetts General Hospital, Boston, Massachusetts, United States of America
| | - J. Tyson McDonald
- Cancer Research Center, Hampton University, Hampton, Virginia, United States of America
| | - Charusheila Ramkumar
- Department of Cell Biology and Development, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
| | - Tatenda Kadungure
- Department of Cell Biology and Development, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
| | - Hong Zhang
- Department of Cell Biology and Development, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
| | - Ronald B. Gartenhaus
- Marlene & Stewart Greenebaum Cancer Center, Department of Medicine, University of Maryland, Baltimore, Maryland, United States of America
| | - Andrew M. Evens
- Division of Hematology/Oncology, Molecular Oncology Research Institute, Tufts Medical Center, Boston, Massachusetts, United States of America
- * E-mail:
| |
Collapse
|